Resident Doctor, Department of Orthopaedics, the First Hospital of China Medical University, Shenyang, Liaoning, China.
Doctor-in-Charge, Department of Orthopaedics, the First Hospital of China Medical University, Shenyang, Liaoning, China.
J Foot Ankle Surg. 2021 Sep-Oct;60(5):881-886. doi: 10.1053/j.jfas.2021.02.010. Epub 2021 Mar 9.
Few studies have characterized the clinical outcomes of 45S5 Bioglass® applied as a bone graft to that of allogeneic bone applied in calcaneal open curettage. Therefore, the purpose of the present investigation was to compare the outcomes of patients with calcaneal tumors and tumor-like lesions treated by open curettage with 45S5 Bioglass® or allogeneic bone. Of the 31 patients who underwent open curettage (18 cases of unicameral bone cysts, 7 cases of aneurysmal bone cysts, and 6 cases of intraosseous lipoma), 16 (52%) received grafts with 45S5 Bioglass® and 15 (48%) with allogeneic bone. All the feet achieved bone fusion according to the modified Neer radiographic classification system at the last follow-up examination. The mean bone ingrowth time for the grafts with 45S5 Bioglass® versus allogeneic bone was 3.71 ± 0.86 versus 4.46 ± 1.04 months (p = .038), the mean bone healing time was 4.86 ± 0.93 versus 5.73 ± 1.07 months (p = .021), and the mean incision drying time was 7.2 ± 1.8 versus 8.2 ± 1.5 days (p = .047), respectively. No differences were found in the postoperative American Orthopaedic Foot and Ankle Society ankle-hindfoot scale scores between the 2 groups (p = .213). These results show that 45S5 Bioglass® can better facilitate the formation of new bone with a faster drying time of the incision than allogeneic bone. Although both materials can benefit the clinical outcomes of calcaneal tumors and tumor-like lesions, further studies are needed to observe the long-term complications and lesion recurrence rates.
很少有研究对 45S5 生物玻璃作为骨移植物的临床结果进行特征描述，而将其与同种异体骨在跟骨开放性刮除术中的应用结果进行比较。因此，本研究旨在比较应用 45S5 生物玻璃或同种异体骨治疗跟骨肿瘤和肿瘤样病变患者的结果。在接受开放性刮除术的 31 例患者（单房性骨囊肿 18 例，动脉瘤样骨囊肿 7 例，骨内脂肪瘤 6 例）中，16 例（52%）采用 45S5 生物玻璃植骨，15 例（48%）采用同种异体骨植骨。末次随访时，所有患者均根据改良 Neer 放射学分类系统达到骨融合。45S5 生物玻璃植骨组与同种异体骨植骨组的植骨骨内生长时间分别为 3.71±0.86 个月和 4.46±1.04 个月（p=0.038），骨愈合时间分别为 4.86±0.93 个月和 5.73±1.07 个月（p=0.021），切口干燥时间分别为 7.2±1.8 天和 8.2±1.5 天（p=0.047）。两组术后美国矫形足踝协会踝-后足评分无差异（p=0.213）。这些结果表明，与同种异体骨相比，45S5 生物玻璃可以更好地促进新骨形成，并更快地干燥切口。虽然这两种材料都可以改善跟骨肿瘤和肿瘤样病变的临床结果，但需要进一步研究来观察长期并发症和病变复发率。
